|
Keryx Biopharmaceuticals, Inc.
Ticker Symbol: KERX* CUSIP: 492515101 Exchange: NCM
* NOTE: This security is no longer trading as of 12/13/18
Company's Online Profile
BUSINESS: Keryx Biopharmaceuticals, Inc. focuses on the acquisition, development & commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease & cancer.
|
Notes: Dec. 13, 2018 -- Akebia Therapeutics, Inc. (Nasdaq:AKBA) and Keryx Biopharmaceuticals, Inc.today announced the successful completion of their previously announced merger.
|
IPO - 7/28/2000 - 4.60 Million Shares @ $10.00/share.
Link to IPO Prospectus
Small Cap Stock -
Market Value $ 500 Million
Yahoo News Summary for KERX*
YAHOO! Profile for KERX*
Yahoo Detailed Quote
MarketWatch Quote
MSN Company Report for KERX*
|
Company's Online Information Links
|
| Company's Online SEC EDGAR Filings |
| Company's Email Address Links |
| Address and Phone Numbers |
| Address: One Marina Park Drive, 12th Floor, Boston, MA 10022 |
| Main Phone Number |
617-466-3500 |
| Fax Number |
617-466-3500 |
| Investor Relations
Lora Pike
|
617-466-3511
|
Toll Free Phone Number |
Unknown |
| CEO - Gregory Paul Madison |
CFO - Scott A. Holmes |
Find a problem? Please use our Feedback Page or Email us.
Have you filled out our Guestbook? If not, please do.
|
|
